Moderna’s (MRNA) “Hold” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Moderna (NASDAQ:MRNA) in a research note published on Friday, Benzinga reports.

MRNA has been the topic of a number of other reports. The Goldman Sachs Group decreased their price target on Moderna from $204.00 to $178.00 and set a buy rating on the stock in a research note on Friday, August 2nd. HSBC upgraded Moderna from a reduce rating to a hold rating and set a $82.00 price target on the stock in a research note on Wednesday, August 28th. Piper Sandler decreased their price target on Moderna from $157.00 to $115.00 and set an overweight rating on the stock in a research note on Friday. Hsbc Global Res upgraded Moderna from a moderate sell rating to a hold rating in a research note on Wednesday, August 28th. Finally, Royal Bank of Canada cut Moderna from an outperform rating to a sector perform rating and decreased their price target for the stock from $125.00 to $90.00 in a research note on Monday, August 5th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of Hold and a consensus price target of $108.53.

Moderna Trading Down 2.0 %

Shares of Moderna stock opened at $68.28 on Friday. The firm has a market capitalization of $26.17 billion, a price-to-earnings ratio of -4.36 and a beta of 1.67. Moderna has a fifty-two week low of $62.55 and a fifty-two week high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The stock has a 50 day moving average of $95.06 and a 200 day moving average of $111.68.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm’s revenue for the quarter was down 29.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($3.62) earnings per share. As a group, research analysts predict that Moderna will post -9.52 earnings per share for the current year.

Insider Activity at Moderna

In related news, President Stephen Hoge sold 15,000 shares of the stock in a transaction on Monday, June 17th. The stock was sold at an average price of $138.16, for a total value of $2,072,400.00. Following the transaction, the president now owns 1,457,089 shares of the company’s stock, valued at $201,311,416.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Moderna news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the transaction, the president now owns 1,457,089 shares of the company’s stock, valued at $201,311,416.24. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. The disclosure for this sale can be found here. Insiders have sold 108,158 shares of company stock valued at $13,239,712 over the last quarter. 15.70% of the stock is owned by insiders.

Institutional Trading of Moderna

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in shares of Moderna by 15.1% in the first quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock valued at $4,159,769,000 after buying an additional 5,129,800 shares during the last quarter. Wellington Management Group LLP increased its position in Moderna by 28.8% in the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after acquiring an additional 1,614,460 shares during the period. Capital World Investors raised its stake in Moderna by 0.5% during the 1st quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock valued at $388,743,000 after acquiring an additional 18,728 shares during the last quarter. Norges Bank purchased a new position in shares of Moderna in the 4th quarter valued at approximately $347,565,000. Finally, Mawer Investment Management Ltd. grew its stake in shares of Moderna by 6.7% in the 1st quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock valued at $204,230,000 after purchasing an additional 120,621 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.